Seminars in Oncology
Volume 32, Issue 1 , Pages 76-84 , February 2005

Colorectal cancer vaccines: What we know and what we don’t yet know

  • Margaret von Mehren

      Affiliations

    • Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • Corresponding Author InformationAddress reprint requests to Margaret von Mehren, MD, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111

References 

  1. Pardoll DM . Cancer vaccines . Nature Med . 1998;4(suppl 5):525–531
  2. Liu JY , Wei YQ , Yang L , et al.   Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2 . Blood . 2003;102:1815–1823
  3. He QM , Wei YQ , Tian L , et al.   Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice . J Biol Chem . 2003;278: 21831-21816
  4. Zimmermann W , Weber B , Ortlieb B , et al.   Chromosomal localization of the carcinoembryonic antigen gene family and differential expression in various tumors . Cancer Res . 1988;48:2550–2554
  5. Shively JE , Beatty JD . CEA-related antigens (Molecular biology and clinical significance) . Crit Rev Oncol Hematol . 1985;2:355–399
  6. Esteban JM , Felder B , Ahn C , et al.   Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients . Cancer . 1994;74:1575–1583
  7. Wagener C , Petzold P , Kohler W , et al.   Binding of five monoclonal anti-CEA antibodies with different epitope specificities to various carcinoma tissues . Int J Cancer . 1984;33:469–475
  8. Chung JK , Lee MC , Chung HK , et al.   Concentration and distribution of tumor associated antigens TAG-72 and CEA in stomach cancer . Ann Nucl Med . 1995;9:7–13
  9. Brezicka FT , Olling S , Bergman B , et al.   Coexpression of ganglioside antigen Fuc-GM1, neural-cell adhesion molecule, carcinoembryonic antigen, and carbohydrate tumor-associated antigen CA 50 in lung cancer . Tumour Biol . 1992;13:308–315
  10. Yewdell JW , Bennink JR . The binary logic of antigen processing and presentation to T cells . Cell . 1990;62:203–206
  11. Hahn YS , Yang B , Braciale TJ . Regulation of antigen processing and presentation to class I MHC restricted CD8+ T lymephocytes . Immunol Rev . 1996;151:31–49
  12. Jerne NK . Towards a network theory of the immune system . Ann Immunol . 1974;125C:373–389
  13. Lindenmann J . Speculations on idiotypes and homobodies . Ann Immunol . 1973;124:171–184
  14. Shawler DL , Bartholomew RM , Garrett MA , et al.   Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine . Clin Exp Immunol . 2002;129:99–106
  15. Sobol RE , Shawler DL , Carson C , et al.   Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts (A phase I study) . Clin Cancer Res . 1999;5:2359–2365
  16. Hoover HC , Brandhorst JS , Peters LC , et al.   Adjuvant active specific immunotherapy for human colorectal cancer (6.5-year median follow-up of a phase III prospectively randomized trial) . J Clin Oncol . 1993;11:390–399
  17. Harris J , Ryan L , Adams G , et al.   Survival and relapse in adjuvant autologous tumour vaccine therapy for Dukes B and C colon cancer-EST 5283 . Proc Am soc Clin Oncol . 1994;13:294; (abstr)
  18. Vermorken JB , Claessen AM , van Tinteren H , et al.   Active specific immunotherapy for stage II and stage III human colon cancer (A randomized trial) . Lancet . 1999;353:345–350
  19. Zaremba S , Barzaga E , Zhu M , et al.   Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen . Cancer Res . 1997;57:4570–4577
  20. Huarte E , Sarobe P , Lu J , et al.   Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements . Clin Cancer Res . 2002;8:2336–2344
  21. Palena C , Arlen P , Zeytin  , et al.   Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens . Cytokine . 2003;24:128–142
  22. Samanci A , Yi Q , Fagerberg J , et al.   Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen . Cancer Immunol Immunother . 1998;47:131–142
  23. Morse MA , Deng Y , Coleman D , et al.   A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen . Clin Cancer Res . 1999;5:1331–1338
  24. Alters SE , Gadea JR , Sorich M , et al.   Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire . J Immunother . 1998;21:17–26
  25. Nair SK , Hull S , Coleman D , et al.   Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA . Int J Cancer . 1999;82:121–124
  26. Srivastava P . Interaction of heat shock proteins with peptides and antigen presenting cells (Chaperoning of the innate and adaptive immune responses) . Annu Rev Immunol . 2002;20:395–425
  27. Hartl FU , Hayer-Hartl M . Molecular chaperones in the cytosol (From nascent chain to folded protein) . Science . 2002;295:1852–1858
  28. Rivoltini L , Castelli C , Carrabba M , et al.   Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells . J Immunol . 2002;171:3467–3474
  29. Mazzaferro V , Coppa J , Carrabba MG , et al.   Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer . Clin Cancer Res . 2003;9:3235–3245
  30. Durrant L , Denton G , Jacobs E , et al.   An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours . Int J Cancer . 1992;50:811–816
  31. Foon KA , Chakraborty M , John WJ , et al.   Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine . J Clin Invest . 1995;96:334–342
  32. Foon KA , John WJ , Chakraborty M , et al.   Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen . Clin Cancer Res . 1997;3:1267–1276
  33. Chatterjee SK , Tripathi PK , Chakraborty M , et al.   Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody . Cancer Res . 1998;58:1217–1224
  34. Foon KA , John WJ , Chakraborty M , et al.   Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen . J Clin Oncol . 1999;17:2889–2895
  35. Baral NB , Saha A , Chatterjee SK , et al.   Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen . Cancer Immunol Immunother . 2003;52:317–327
  36. Cohen AD , Boyer JD , Weiner DB . Modulating the immune response to genetic immunization . FASEB J . 1998;12:1611–1626
  37. Conry RM , White SA , Fultz PN , et al.   Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen . Clin Cancer Res . 1998;4:2903–2912
  38. Conry R , Curiel D , Strong T , et al.   Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients . Clin Cancer Res . 2002;8:2782–2787
  39. Nair SK , Boczkowski D , Morse M , et al.   Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA . Nature Biotechnol . 1998;16:364–369
  40. Nair S , Morse M , Boczkowski D , et al.   Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells . Ann Surg . 2002;235:540–549
  41. McAneny D , Ryan CA , Beazley RM , et al.   Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer . Ann Surg Oncol . 1996;3:495–500
  42. Conry RM , Khazaeli MB , Saleh MN , et al.   Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma (Comparison of intradermal versus subcutaneous administration) . Clin Cancer Res . 1999;5:2330–2337
  43. Conry R , Alen K , Lee S , et al.   Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine . Clin Cancer Res . 2000;6:34–41
  44. Tsang KY , Zaremba S , Nieroda CA , et al.   Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine . J Natl Cancer Inst . 1995;87:982–990
  45. Taylor J , Trimarchi C , Weinberg R , et al.   Efficacy studies on a canary pox-rabies recombinant virus . Vaccine . 1991;9:190–193
  46. Taylor J , Weinberg R , Tartaglia J , et al.   Nonreplicating viral vectors as potential vaccines (Recombinant canary pox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins) . Virology . 1992;187:321–328
  47. Nelson J . The behavior of pox viruses in the respiratory tract. IV. The nasal instillation of fowlpox virus in chickens and in mice . J Exp Med . 1941;74:203–211
  48. Kent SJ , Zhao A , Best SJ , et al.   Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus . J Virol . 1998;72:10180–10188
  49. Coupar BE , Teo T , Boyle DB . Restriction endonuclease mapping of the fowlpox virus genome . Virology . 1990;179:159–167
  50. Liu X , Peng D , Wu X , et al.   A recombinant fowlpox virus vaccine expressing glycoprotein B gene from CVI988/Rispens strain of MDV (Protection studies in different chickens) . Acta Virol . 1999;43:201–204
  51. Heine HG , Foord AJ , Young PL , et al.   Recombinant fowlpox virus vaccines against Australian virulent Marek’s disease virus (Gene sequence analysis and comparison of vaccine efficacy in specific pathogen free and production chickens) . Virus Res . 1997;50:23–33
  52. Girard M , Meignier B , Barre-Sinoussi F , et al.   Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 . J Virol . 1995;69:6239–6248
  53. Tartaglia J , Jarrett O , Neil JC , et al.   Protection of cats against feline leukemia virus by vaccination with a canary pox virus recombinant, ALVAC-FL . J Virol . 1993;67:2370–2375
  54. Egan MA , Pavlat WA , Tartaglia J , et al.   Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canary pox vector (ALVAC) carrying the HIV-1MN env gene . J Infect Dis . 1995;171:1623–1627
  55. Cadoz M , Strady A , Meignier B , et al.   Immunization with canary pox virus expressing rabies glycoprotein . Lancet . 1992;339:1429–1432
  56. Robinson HL , Montefiori DC , Johnson RP , et al.   Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations . Nat Med . 1999;5:526–534
  57. Marshall JL , Hawkins MJ , Tsang KY , et al.   Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen . J Clin Oncol . 1999;17:332–337
  58. Zhu MZ , Marshall J , Cole D , et al.   Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine . Clin Cancer Res . 2000;6:24–33
  59. Marshall JL , Hoyer RJ , Toomey MA , et al.   Phase I study in cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic immune responses . J Clin Oncol . 2000;20:2251–2266
  60. von Mehren M , Arlen P , Tsang KY , et al.   Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas . Clin Cancer Res . 2000;6:2219–2228
  61. von Mehren M , Arlen P , Gulley J , et al.   The influence of GM-CSF and prior chemotherapy on the immunologic response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma . Clin Cancer Res . 2001;7:1181–1191
  62. Horig H , Lee DS , Conkright W , et al.   Phase I clinical trial of a recombinant canary poxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule . Cancer Immunol Immunother . 2000;49:504–514
  63. Rothlein R , Dustin M , Marlin S , et al.   A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1 . J Immunol . 1986;37:1270–1274
  64. Makgoba MW , Sanders ME , Shaw S . The CD2-LFA-3 and LFA-1-ICAM pathways (Relevance to T-cell recognition) . Immunol Today . 1989;10:417–422
  65. Steinman RM . The dendritic cell system and its role in immunogenicity . Annu Rev Immunol . 1991;9:271–296
  66. Dustin ML , Springer TA . Role of lymphocyte adhesion receptors in transient interactions and cell locomotion . Annu Rev Immunol . 1991;9:27–66
  67. Bierer B , Barbosa J , Herrmann S , et al.   Interaction of CD2 with its ligand, LFA-3, in human T cell proliferation . J Immunol . 1988;140:3358–3363
  68. Hodge JW , Sabzevari H , Gomez A , et al.   A triad of costimulatory molecules synergize to amplify T-cell activation . Cancer Res . 1999;59:5800–5807
  69. von Mehren M . Tumor vaccines . 2003; Presented at the 4th Annual Perspectives in Colorectal Cancer, Washington, DC, September 12
  70. Marshall J , Odogwu L , Hwang J , et al.   A phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM (B7.1/ICAM-1/LFA-3) alone, and sequentially with vaccinia-CEA (6D)-TRICOM and GM-CSF in patients with CEA-expressing carcinomas . Proc Am Soc Clin Oncol . 2003;22:165; (abstr 662)
  71. Jones T , Stern A , Lin R . Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant . Eur J Clin Microbiol Infect Dis . 1994;13(suppl):S47–S53
  72. Morrissey PJ , Bressler L , Park LS , et al.   Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells . J Immunol . 1987;139:1113–1119
  73. Dranoff G , Jaffee E , Lazenby A , et al.   Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity . Proc Natl Acad Sci U S A . 1993;90:3539–3543
  74. Prete S , Aquino A , Masci G , et al.   Drug-induced changes of carcinoembryonic antigen expression in human cancer cells (Effects of 5-fluorouracil) . J Pharmacol Exp Ther . 1996;279:1574–1581
  75. Aquino A , Prete S , Greiner J , et al.   Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells . Clin Cancer Res . 1998;4:2473–2481
  76. Linsley PS , Brady W , Urnes M , et al.   CTLA-4 is a second receptor for the B cell activation antigen B7 . J Exp Med . 1991;174:561–569
  77. Bugeon L , Dallman M . Costimulation of T cells . Am J Respir Crit Care Med . 2000;162:S164–S168
  78. Greenfield E , Nguyen K , Kuchroo V . CD28/B7 costimulation (A review) . Crit Rev Immunol . 1998;18:389–418
  79. Chambers C , Allison J . Co-stimulation in T cell responses . Curr Opin Immunol . 1997;9:396–404
  80. Weber JS , Snively J , Sian S , et al.   Phase I trial of antibody to CTLA-4 (MDX-010) with melanoma peptides/Ifa for resected stages III/IV melanoma . Proc Am Soc Clin Oncol . 2003;22:710; (abstr 2853)

 Supported in part by 1R21 CA92992-01. Dr von Mehren has served as an advisor to Aventis-Pasteur and Novartis Oncology. She received less than $5,000 in honoraria from each company in 2003.

PII: S0093-7754(04)00462-2

doi: 10.1053/j.seminoncol.2004.09.033

Seminars in Oncology
Volume 32, Issue 1 , Pages 76-84 , February 2005

Article Tools

* Image Usage & Resolution